

## **PRESS RELEASE**

*This press release may constitute a public disclosure of inside information by Kepler S.p.A. under Regulation (EU) 596/2014 and Commission Implementing Regulation (EU) 2016/1055.*

### **Biofarma Group appoints Alberto Urli as new Chief Executive Officer**

Mereto di Tomba (Udine, Italy) - The Biofarma Group – a **leading global nutraceuticals and cosmetics CDMO**, focused on delivering to clients **outstanding service, innovation and manufacturing excellence** – announces the appointment of **Alberto Urli** as new **CEO** of the **Group**.

**Alberto** has delivered impressive performance since joining the Group in 2022 and has **played a key role in transforming Biofarma into a truly multinational company**, establishing unified processes and service standards across countries. As Chief Operating Officer of the Group, he was instrumental in enhancing service excellence towards customers, advancing scientific innovation and improving manufacturing excellence. Furthermore, Alberto oversaw the two strategic investments in France and the US, showcasing the Biofarma Group's commitment to keep clients at the heart of the business.

**Germano Scarpa** – Founder & Chairman of Biofarma and who has led the Group as CEO over the last 15 months – will **continue to support Biofarma as Chairman** of Biofarma, ensuring clients' continuity and alignment on the key values on which he and Gabriella Tavasani founded Biofarma almost 40 years ago.

Biofarma Group is also pleased to welcome **Jonathan Arnold** as **Chairman of the holding company of the Biofarma Group**. His extensive and global experience in the CDMO industry at leading firms such as Catalent and Patheon, will help the Biofarma Group to further strengthen its leading position at a global level.

This **leadership transition** will further strengthen the Biofarma Group's **commitment to service, innovation and excellence** to employees, clients, and partners, in **continuity with its history**. Biofarma is strongly focused on strengthening the company's position as a leading global nutraceutical and cosmetics CDMO, developing innovative solutions and technologies to improve people's health and well-being in a sustainable way.

*“It is an honor and a great responsibility to take on the role of CEO of Biofarma Group. Over the past years, I have witnessed the strength of our teams and the passion driving every project: we will continue to support the success of our clients, strengthening innovation, excellence, and sustainability. We look to the future with determination, ready to further consolidate our global leadership.”* – Alberto Urli, CEO of Biofarma Group

*“When a company chooses its new CEO from within, it sends a powerful message: ambition can be fulfilled, and personal growth is truly valued. The appointment of Alberto Urli is not just a choice of continuity; it brings fresh energy and is a catalyst that will energize the entire organization and bring us even closer to our clients.”* – Germano Scarpa, Founder & Chairman of Biofarma

\*\*\* \*\*

## **Biofarma Group**

With over €450 million in revenue and over 1,500 employees, Biofarma Group is a leading global nutraceuticals and cosmetics CDMO, focused on delivering to clients outstanding service, innovation and manufacturing excellence. The Group operates 9 production sites, including 3 in Italy, 2 in France, 3 in the US, and 1 in China, and serves its customers in over 75 countries.

\*\*\* \*\*

### ***Forward Looking Statements***

*This press release may include “forward-looking statements” within the meaning of the securities laws of applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this press release, including, without limitation, those regarding the Biofarma Group’s intentions, beliefs or current expectations concerning, among other things, its strategy, plans, objectives, prospects, growth, goals and targets. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “seek” or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future.*